Zagori: Pharmaceutical company support reference pricing
- True
Zagori: Pharmaceutical company support reference pricing
According to him, the Ukrainian medicine in today’s environment are 4-5 times less than imported, although produced by the same technology and have the same active ingredients.
Reference pricing is an optimal mechanism for regulating the prices of medicines, and Ukrainian producers support the decision of the Cabinet on its implementation. About it RBC said the MP, co-owner of the pharmaceutical company “Darnitsa” Gleb zagoriy.
“I, for its part, has consistently defended its introduction, and President Petro Poroshenko, by the way, in 2015 in favor of this method of regulation of prices for medicines. I welcome the decision to introduce reference pricing for three groups of drugs, and I am sure that in near future it will affect more than half of the medicines that are present on the Ukrainian market. In this way the state will protect patients from unnecessary uneconomic expenditure of money,” said zagari.
According to him, the Ukrainian medicine in today’s environment are 4-5 times less than imported, although produced by the same technology and have the same active ingredients.
“Ukrainians continue to impose a stereotype that all imported quality, and domestic – no. And that is why more than 50% of Ukrainians believe the price of drugs too large. A simple example of buying at the pharmacy of the same set of medicines to Ukrainian and foreign production with the same composition, and at the price differs by almost 6 times: 416 UAH Ukrainian hryvnia and 2532 for import. As the Ukrainian consumer can save? Elementary – you need to ask the doctor or the pharmacist what the drug active ingredient, and buy medicine of Ukrainian production”, – said zagari.
As the newspaper notes, the government has included in the draft Budget for 2017 500 million UAH for compensation of cost of medicines (the reimbursement) and at the last meeting of the Cabinet of Ministers has introduced reference pricing for three groups of drugs. Reimbursement, according to the decision of the government, will work from 1 April 2017.